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interval [CI]: 64-89%) and 95.8% (95% CI: 90-100%) respectively. 
Thirteen pts presented LR failures, of which 4 had isolated local 
failure, 4 had isolated regional failure, 2 had local and regional 
failures, and 3 had simultaneous LR and distant relapses. Of 13 pts 
with LR relapse, only 1 (8%) had marginal failure, with the remaining 
92% failing truly in-field within the high-dose region. No patient 
recurred in vicinity of spared PG, SMG or OC. Surgical salvage for LR 
failure was attempted in 5 pts. Contralateral PG was spared in 98% of 
pts and ipsilateral PG in 54%. Concerning SMGs, 18 (26%) contralateral 
glands were spared and the ipsilateral SMG was spared in 5 pts. In 
other 13 (19%) pts doses to the SMGs below 50 Gy were obtained. The 
OC was spared to a dose ≤40 Gy in 26 pts (37%). None of the pts 
developed permanent xerostomia higher than grade 2 at the last 
follow-up visit. 
Conclusions: The majority of LR failures occurred in-field within the 
high dose region. Sparing SMGs and OC in addition to PGs does not 
seem to jeopardize the LR control in HNC IMRT.  
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Purpose/Objective: To evaluate the role of pretreatment dual-phase 
18F-FDG-PET maximum standardized uptake (SUVmax) in predicting 
the outcome of nasopharyngeal carcinoma (NPC). 
Materials and Methods: A total of 140 patients with newly diagnosed 
NPC were prospectively treated with IMRT plus neoadjuvant or 
concurrent chemotherapy between January 2006 and December 2008. 
Pretreatment SUVmax at 60 minutes (SUV1) and 150 minutes (SUV2) 
after injection of 18F-FDG were collected. We investigated the effects 
of SUVmax of primary tumor (SUV1-primary, SUV-2-primary) and neck 
lymph nodes (SUV1-neck, SUV2-neck) on locoregional failure-free 
survival (LRFFS), distant metastasis failure-free survival (DMFFS) and 
overall survival (OS). 
Results: In univariate analysis, the 5-year rate of OS for patients with 
SUV1-primary <12.9 was significantly higher than those with SUV1-
primary ?12.9 (87.0% and 72.2%, p=0.044). SUV2-primary, SUV1-neck 
and SUV2-neck did not affect OS significantly. All SUVs of primary 
tumor and neck lymph nodes have significant effects on DMFFS (SUV1-
primary < vs. ?12.5=89.1% vs. 70.8%, p=0.004; SUV2-primary < vs. 
?12.8=88.6% vs. 76.4%, p=0.022; SUV1-neck < vs. ?8.1=91.0% vs. 71.8%, 
p=0.003; and SUV2-neck < vs. ?3.7=94.7% vs. 80.5%, p=0.024, 
respectively). All SUVs had no significant effect on LRFFS. In 
multivariate analysis, except for N stage, SUV1-primary, SUV2-primary 
and SUV1-neck were significantly independent predictors of DMFFS 
(hazard ratio=4.313, 95% CI=1.447~12.855, p=0.009; hazard 
ratio=4.399, 95% CI=1.514~12.785, p=0.006; and hazard ratio=3.769, 
95% CI=0.985~14.420, p=0.053, respectively). 
Conclusions: The SUV1- primary predicts OS by univariate analysis. 
The SUV1-primary, SUV2-primary and SUV1-neck were independently 
prognostic factors of distant failure.  
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Purpose/Objective: To create Helical Tomotherapy (HT) plans for t 
treating patients with oropharyngeal cancer (OPC) with the same 
treatment time as RapidArc (RA) Volumetric Modulated Arc Therapy 
(VMAT).  
Materials and Methods: We made both a double arc RA plan on 
Eclipse and a standard HT plan on TomoHDTM according to the ICRU 83 
guidelines in 5 OPC patients. In 32 fractions, a simultaneous 
integrated boost technique was planned to deliver 69.12 Gy (2,16 Gy / 
fraction) to the high risk volume (PTV of the GTV + 1cm) and 56 Gy 
(1.75 Gy / fraction) to the PTV of the remaining primary tumor region 
and the bilateral elective lymph node regions. Guidelines for all the 
organs at risk (OARs) were given. By modifying the beam width from 
2.5 cm to 5.0 cm, elevating the pitch and lowering the modulation 
factor, we created 'Tomo Fast (TF) plans in which treatment times 
were equal to those in the RA plans. The homogeneity index (HI), the 
conformity index (CI), the mean dose, the Dnear-max (D2) and the 
Dnear-min (D98) of the PTVs were analyzed as well as the mean dose 
and specific critical doses and volumes of 26 OARs . Differences 
between the individual plans of the treatment planning systems were 
analyzed using repeated measures ANOVA. 
Results: With a mean treatment time of 3.05 min for RA and 2.89 min 
for TF , PTVboost coverage was more homogeneous with TF (mean HI 
.07; SE .01) than with RA (mean HI .10; SE .01). while PTVelective was 
most homogeneous with RA. Mean doses to the parotid glands were 
identical for RA and TF: 25.62 Gy and 25.34 Gy for the contralateral 
and 32.02 Gy and 31.96 Gy for the ipsilateral gland, respectively. 
Spinal cord, cricopharyngeal muscle and cranial part of the esophagus 
received a lower mean dose when planned with TF, the glottic larynx 
when planned with RA. V20 of the lungs, mean dose of inner ears, 
brain and eyes, and the integral dose were higher with TF than with 
RA, probably due the 5 cm beam width related cranial-caudal gradient 
extension. For details, see enclosed Table. 
 
  
Conclusions: This study shows that it is possible to treat OPC patients 
with TF as fast as with RA while giving comparable target coverage 
and sparing of most critical organs. However, with TF the higher dose 
to the organs at the cranial and caudal end of the target volume and 
the higher integral dose, both due to the extended cranial-caudal 
gradient, needs consideration. Moreover, compared to regular HT, 
both these faster techniques lose a (major) part of HT’s OAR sparing 
capacity. 
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Purpose/Objective: Optimisation of swallowing outcome after 
curative radiotherapy is multifaceted and requires maintaining the 
functional integrity of multiple pharyngeal axis structures. Recent 
dose/volume/outcome data (DVO)demonstrates a correlation between 
laryngeal dose and late dysphagia complication. Accurate and reliable 
DVO data demands consistent delineation, yet several guidelines for 
the delineation of the pharyngeal axis exist. This is a comparative 
study of two delineation guidelines of the pharyngeal axis and the 
implications that differences between them may have on dosimetry.  
Materials and Methods: The pharyngeal axis (inclusive of superior 
(SPCM), middle (MPCM) and inferior pharyngeal constrictors (IPCM), 
cricopharyngeus(CP), oesophageal inlet (OI)) were retrospectively 
contoured by one clinician on five consecutive patients with SCC head 
and neck, utilising two different sets of delineation guidelines (G1 (1) 
